# CVS HEALTH Corp: Form 10-Q for the period ended Jun 30, 2009

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2009-08-04
- Accepted by EDGAR: Aug 4, 2009, 17:01 ET
- Period: 2009-06-30
- Accession: 0001193125-09-163865
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000119312509163865/d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000119312509163865/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2009-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2009-04-01 to 2009-06-30 | $24.87bn | us-gaap:Revenues |
| Revenue | 6 months, 2009-01-01 to 2009-06-30 | $48.27bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2009-04-01 to 2009-06-30 | $19.82bn | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2009-01-01 to 2009-06-30 | $38.46bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2009-04-01 to 2009-06-30 | $5.05bn | us-gaap:GrossProfit |
| Gross profit | 6 months, 2009-01-01 to 2009-06-30 | $9.80bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2009-04-01 to 2009-06-30 | $1.60bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2009-01-01 to 2009-06-30 | $2.98bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2009-04-01 to 2009-06-30 | $582.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2009-01-01 to 2009-06-30 | $1.07bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2009-04-01 to 2009-06-30 | $886.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2009-01-01 to 2009-06-30 | $1.62bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2009-04-01 to 2009-06-30 | $0.60 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2009-01-01 to 2009-06-30 | $1.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2009-04-01 to 2009-06-30 | $0.61 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2009-01-01 to 2009-06-30 | $1.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2009-04-01 to 2009-06-30 | 1,471,800,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2009-01-01 to 2009-06-30 | 1,469,900,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2009-01-01 to 2009-06-30 | $1.32bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2009-01-01 to 2009-06-30 | $1.09bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2009-01-01 to 2009-06-30 | $220.7m | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months, 2009-01-01 to 2009-06-30 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2009-06-30 | $1.23bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2009-06-30 | $16.77bn | us-gaap:AssetsCurrent |
| Total assets | at 2009-06-30 | $61.04bn | us-gaap:Assets |
| Current liabilities | at 2009-06-30 | $12.76bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2009-06-30 | $7.31bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2009-06-30 | $2.40bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2009-06-30 | $1.33bn | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2009-06-30 | $36.15bn | us-gaap:StockholdersEquity |

## Market risk

As filed, 287 characters.

As of June 30, 2009, the Company had no derivative financial instruments or derivative commodity instruments in place and believes that its exposure to market risk associated with other financial instruments, principally interest rate risk inherent in its debt portfolio is not material.

## Controls and procedures

As filed, 5,915 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of June 30, 2009, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 that occurred during the second quarter ended June 30, 2009 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Legal Proceedings

See Item 3 of Part I to our Annual Report on Form 10-K for the fiscal year ending December 31, 2008 for disclosure relating to material pending legal proceedings. Set forth below is a summary of material developments involving a material pending legal proceeding that occurred subsequent to the filing of our 10-K.

1\. Caremark’s subsidiary Caremark, Inc. (now known as Caremark, L.L.C.) is a defendant in a *qui tam* lawsuit initially filed by a relator on behalf of various state and federal government agencies in Texas federal court in 1999. The case was unsealed in May 2005. The case seeks money damages and alleges that Caremark’s processing of Medicaid and certain other government claims on behalf of its clients (which allegedly resulted in underpayments from our clients to the applicable government agencies) violates applicable federal or state False Claims Acts and fraud statutes. The United States and the States of Texas, Tennessee, Florida, Arkansas, Louisiana and California intervened in the lawsuit, but Tennessee and Florida withdrew from the lawsuit in August 2006 and May 2007, respectively. The parties previously filed cross motions for partial summary judgment, and in August 2008, the court granted several of Caremark’s motions and denied the motions filed by the plaintiffs. The court’s recent rulings are favorable to Caremark and substantially limit the ability of the plaintiffs to assert False Claims Act allegations or statutory or common law theories of recovery based on Caremark’s processing of Medicaid and other government reimbursement requests. The state plaintiffs and the relator filed motions asking the court to reconsider its rulings, and these motions were recently denied. The United States is seeking an appeal of the court’s rulings. In April 2009, the State of Texas filed a purported civil enforcement action against Caremark for injunctive relief, damages and civil penalties in Travis County, Texas alleging that Caremark violated the Texas Medicaid Fraud Prevention Act and other state laws based on our processing of Texas Medicaid claims on behalf of PBM clients. The claims and issues raised in this lawsuit are related to the claims and issues pending in the federal *qui tam* lawsuit described above.

### Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of equity securities and use of proceeds during the quarter ended June 30, 2009.

### Submission of Matters to a Vote of Security Holders

The following matters were submitted to a vote of security holders at our Annual Meeting of Stockholders which was held on Wednesday, May 6, 2009 in Woonsocket, Rhode Island.

| 1. | The election, for one-year terms, of all persons nominated for directors, as set forth in the Company’s proxy statement dated March 24, 2009, was approved by the following votes: | For | Against | Abstained | Broker Non-Votes |
| --- | --- | ---: | ---: | ---: | ---: |
|  | Edwin M. Banks | 1,232,727,887 | 19,673,728 | — | — |
|  | C. David Brown II | 1,188,852,378 | 63,536,078 | — | — |
|  | David W. Dorman | 1,186,662,663 | 65,619,203 | — | — |
|  | Kristen Gibney Williams | 1,232,086,945 | 20,103,668 | — | — |
|  | Marian L. Heard | 1,232,275,894 | 19,784,465 | — | — |
|  | William H. Joyce | 1,222,371,085 | 29,695,781 | — | — |
|  | Jean-Pierre Millon | 1,189,180,264 | 62,937,074 | — | — |
|  | Terrence Murray | 1,146,516,972 | 105,550,133 | — | — |
|  | C.A. Lance Piccolo | 1,180,196,998 | 71,896,712 | — | — |
|  | Sheli Z. Rosenberg | 1,153,362,943 | 98,297,135 | — | — |
|  | Thomas M. Ryan | 1,196,833,996 | 55,425,246 | — | — |
|  | Richard J. Swift | 1,207,671,769 | 44,385,109 | — | — |
| 2. | Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2009 fiscal year, was approved by the following vote: | 1,242,484,285 | 9,445,681 | 1,915,154 | — |
| 3. | Stockholder proposal regarding special shareholder meetings, as set forth in the Company’s proxy statement dated March 24, 2009, was approved by the following vote: | 699,475,075 | 441,387,593 | 2,801,694 | 313,731,158 |
| 4. | Stockholder proposal regarding independent chairman of the board, as set forth in the Company’s proxy statement dated March 24, 2009, was rejected by the following vote: | 517,241,672 | 621,612,396 | 4,810,293 | 313,731,158 |
| 5. | Stockholder proposal regarding political contributions and expenditures, as set forth in the Company’s proxy statement dated March 24, 2009, was rejected by the following vote: | 373,747,558 | 571,293,648 | 198,623,155 | 313,731,158 |
| 6. | Stockholder proposal regarding advisory stockholder vote on executive compensation, as set forth in the Company’s proxy statement dated March 24, 2009, was approved by the following vote: | 675,251,872 | 421,189,826 | 47,222,664 | 313,731,158 |

37

### Exhibits

Filed Aug 4, 2009.
Source: SEC EDGAR, the filing index for accession 0001193125-09-163865. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
